disease 1,238 words KG: ent-dise-2649b7a0 2026-03-29
kind:diseasesection:diseasestopic:psp
Contents

Speech and Voice Disorders in PSP

Disease Info
Hypophoniasignificantly reduced vocal loudness, often requiring the patient to be reminded to speak louder
Monotonous pitchflat intonation with reduced pitch variation
Articulatory imprecisionfuzzy or slurred consonants, particularly plosives and fricatives
Phonatory insufficiencybreathy, rough voice quality
Articulatory gropingsearching movements of the lips and tongue during speech initiation
Inconsistent phonemic errorsvariable pronunciation of the same word
Lengthened phoneme durationprolonged consonant and vowel sounds
Dysprosodyabnormal stress patterns and rhythm
Substantia nigra pars compactadopaminergic dysfunction affecting speech motor planning
Periaqueductal graymidbrain region involved in vocalization control
Pontine and medullary speech nucleidirect involvement of cranial nerve nuclei governing speech musculature
Reticular formationdisruption of arousal and attention systems necessary for speech initiation
DatabasesOMIMOrphanetClinicalTrialsPubMed

Knowledge Graph

Related Hypotheses (3)

Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67

Related Analyses (9)

4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived

Related Experiments (8)

4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40

See Also (15)

Yoga Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
YAP/TEAD Pathway Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Wnt Signaling Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 3 hypotheses
Vitamin B Complex Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)